Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP1 expression, activity andex vivosensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

2 Nov 2015

Abstract excerpt

// Ashleigh Herriott 1 , Susan J. Tudhope 1 , Gesa Junge 1 , Natalie Rodrigues 2 , Miranda J. Patterson 1 , Laura Woodhouse 1 , John Lunec 1 , Jill E. Hunter 3 , Evan A. Mulligan 1 , Michael Cole 1 , Lisa M. Allinson 4 , Jonathan P. Wallis 5 , Scott Marshall 6 , Evelyn Wang 7 , Nicola J. Curtin 1 and Elaine Willmore 1 1 Newcastle Cancer Centre at the Northern Institute for Cancer Research, Medical School,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chronic Lymphocytic Leukemia Research
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26539646
DOI: 10.18632/oncotarget.6287

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP1 expression, activity andex vivosensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaPMID 26539646Read ↗

A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.Semantic proximity Read ↗

A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphomaSemantic proximity Read ↗

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategiesSemantic proximity Read ↗

PARP (Poly ADP‐ribose Polymerase) Family in Health and DiseaseSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Transcriptional Roles of PARP1 in CancerSemantic proximity Read ↗

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndromeSemantic proximity Read ↗

Distinct roles for PARP-1 and PARP-2 in c-Myc–driven B-cell lymphoma in miceSemantic proximity Read ↗

The Multifactorial Role of PARP-1 in Tumor MicroenvironmentSemantic proximity Read ↗

Targeting ATM-deficient CLL through interference with DNA repair pathwaysSemantic proximity Read ↗

PARP1: Liaison of Chromatin Remodeling and TranscriptionSemantic proximity Read ↗

Molecular Imaging of PARPSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.